Identification of tumor associated immune responses against brachyury, a transcription factor and driver of EMT, in chordoma patients receiving a yeast-brachyury vaccine (gi-6301)

Ítems similars

• Phase I trial of a yeast-based therapeutic cancer vaccine (GI-6301) targeting the transcription factor brachyury
  per: Heery, Christopher R., et al.
  Publicat: (2015)
• Randomized, Double‐Blind, Placebo‐Controlled Phase II Study of Yeast‐Brachyury Vaccine (GI‐6301) in Combination with Standard‐of‐Care Radiotherapy in Locally Advanced, Unresectable Chordoma
  per: DeMaria, Peter Joseph, et al.
  Publicat: (2021)
• PD-1 and PD-L1 expression on PBMC subsets in normal individuals and cancer patients
  per: Lepone, Lauren, et al.
  Publicat: (2014)
• Phase I, dose-escalation, clinical trial of MVA-Brachyury-TRICOM vaccine demonstrating safety and brachyury-specific T cell responses
  per: Heery, Christopher R, et al.
  Publicat: (2015)
• Flow-cytometry phenotypic assessment of immune cell subsets reflecting function for the identification of breast cancer patients receiving vaccine plus docetaxel with longer progression-free survival
  per: Grenga, Italia, et al.
  Publicat: (2013)